178 filings
8-K
ICPT
Intercept Pharmaceuticals, Inc.
8 Nov 23
Entry into a Material Definitive Agreement
4:44pm
8-K
ICPT
Intercept Pharmaceuticals, Inc.
26 Sep 23
Entry into a Material Definitive Agreement
8:28am
8-K
ICPT
Intercept Pharmaceuticals, Inc.
2 Aug 23
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
7:05am
8-K
ICPT
Intercept Pharmaceuticals, Inc.
23 Jun 23
Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
6:35am
8-K
ICPT
Intercept Pharmaceuticals, Inc.
22 Jun 23
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
8:50pm
8-K
dmy7yh0924
25 May 23
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
fsrt59 u7
19 May 23
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
7:27pm
8-K
61j fbooji4h6
17 May 23
Entry into a Material Definitive Agreement
5:43pm
8-K
tjr anyn0
27 Apr 23
Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
7:05am
8-K
oq7 jo002y3xf7rzgm
24 Mar 23
Entry into a Material Definitive Agreement
5:18pm
8-K
fj8o2u8f
2 Mar 23
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance
7:05am
8-K
32kx15ex
27 Feb 23
Other Events
8:00am
8-K
vykr5tkls2y2sltpdz
21 Feb 23
Other Events
8:00am
8-K
crlk0bla0r dlppy
2 Feb 23
Departure of Directors or Certain Officers
5:15pm
8-K
vap0gxhn
25 Jan 23
Other Events
8:00am
8-K
q0z9fbfgi0gk7neuhzl
19 Jan 23
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
8:05am
8-K
jr5p1ws5k9
17 Jan 23
Other Events
8:00am
8-K
etzqb8w8j3gcxqt5df5
11 Jan 23
Regulation FD Disclosure
8:00am
8-K
guusuq 1xc2vgzk
23 Dec 22
Regulation FD Disclosure
8:00am
8-K
b3g9pmfcr8
1 Nov 22
Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
7:05am